ARC-21 (Gastrointestinal Cancer) - Clinical Trial

or email

gi-oncology-cru@dm.duke.edu

¿Cuál es el Propósito de este estudio?

We are doing this study to see if the study drugs, domvanalimab and zimberelimab, are safe and effective for treating advanced or metastatic gastroesophageal adenocarcinoma.

¿Cuál es la Condición que se está estudiando?

Gastroesophageal Adenocarcinoma

¿Quién puede participar en el Estudio?

Adults ages 18+ who are diagnosed with one of the following types of cancer:

Esophageal adenocarcinoma (a common type of cancer of the esophagus); OR
Gastroesophageal junction adenocarcinoma (cancer where the esophagus meets the stomach); OR
Gastric adenocarcinoma (stomach cancer)

The cancer must not be treatable with surgery alone.

Para obtener más información sobre quién puede participar en este estudio, comuníquese con el equipo del estudio al 919-668-1861.

Grupo etario

Adultos

¿Qué Implica?

Si elige unirse a este estudio, podrá:

Receive the study drugs, domvanalimab and zimberelimab, through an IV once every 3 or 4 weeks
Receive standard chemotherapy every 2 weeks in addition to the study drugs (if not previously treated)
Realizar extracciones de sangre
Get CT or MRI scans every 6-to-12 weeks

Detalles del Estudio

Título Completo

A Phase 2 Trial to Evaluate the Safety and Efficacy of Domvanalimab (AB154) and Zimberelimab (AB122) -Based Treatment Combinations in Patients with Advanced Upper Gastrointestinal Tract Malignancies

Investigador Principal